Response to Comments: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms

This policy (A60248) is a response-to-comments notice for the MolDX LCD DL40000 concerning non-NGS tests for diagnosis of BCR-ABL–negative myeloproliferative neoplasms and only records procedural dates (comment period 10/10/2024–11/23/2024; notice period begins 07/03/2025; LCD effective 08/17/2025). It does not itself state coverage indications, limitations, or documentation requirements; refer to LCD DL40000 for the substantive coverage criteria.

"This document is a response to comments and only records the comment period (10/10/2024–11/23/2024), the notice period start (07/03/2025), and the LCD effective date (08/17/2025)."

Sign up to see full coverage criteria, indications, and limitations.